These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 9642622

  • 1. Copolymer-1 in the treatment of multiple sclerosis.
    Boyden KM.
    J Neurosci Nurs; 1998 Apr; 30(2):135-9; quiz 140-1. PubMed ID: 9642622
    [Abstract] [Full Text] [Related]

  • 2. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS.
    Neurology; 1998 Mar; 50(3):701-8. PubMed ID: 9521260
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB.
    Neurology; 1995 Jul; 45(7):1268-76. PubMed ID: 7617181
    [Abstract] [Full Text] [Related]

  • 5. Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone).
    Johnson KP.
    Mult Scler; 1996 Jul; 1(6):325-6. PubMed ID: 9345409
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Copolymer-1.
    Comi G, Moiola L.
    Baillieres Clin Neurol; 1997 Oct; 6(3):495-509. PubMed ID: 10101586
    [Abstract] [Full Text] [Related]

  • 9. Copolymer 1 (glatiramer acetate) in relapsing forms of multiple sclerosis: open multicenter study of alternate-day administration.
    Flechter S, Kott E, Steiner-Birmanns B, Nisipeanu P, Korczyn AD.
    Clin Neuropharmacol; 2002 Oct; 25(1):11-5. PubMed ID: 11852290
    [Abstract] [Full Text] [Related]

  • 10. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, Myers LW, Panitch HS, Pruitt A, Rose JW, Kachuck N, Wolinsky JS.
    Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
    [Abstract] [Full Text] [Related]

  • 11. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.
    Martinelli Boneschi F, Rovaris M, Johnson KP, Miller A, Wolinsky JS, Ladkani D, Shifroni G, Comi G, Filippi M.
    Mult Scler; 2003 Aug; 9(4):349-55. PubMed ID: 12926839
    [Abstract] [Full Text] [Related]

  • 12. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
    Simpson D, Noble S, Perry C.
    BioDrugs; 2003 Aug; 17(3):207-10. PubMed ID: 12749757
    [Abstract] [Full Text] [Related]

  • 13. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J, Belova A, Selmaj K, Wolf C, Sormani MP, Oberyé J, van den Tweel E, Mulder R, Koper N, Voortman G, Barkhof F, Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone (GATE) Study Group.
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [Abstract] [Full Text] [Related]

  • 14. Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1).
    Balabanov R, Lisak D, Beaumont T, Lisak RP, Dore-Duffy P.
    Clin Diagn Lab Immunol; 2001 Nov; 8(6):1196-203. PubMed ID: 11687463
    [Abstract] [Full Text] [Related]

  • 15. Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group.
    Liu C, Blumhardt LD.
    J Neurol Sci; 2000 Dec 01; 181(1-2):33-7. PubMed ID: 11099709
    [Abstract] [Full Text] [Related]

  • 16. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
    Wolinsky JS, Narayana PA, Johnson KP, Multiple Sclerosis Study Group and the MRI Analysis Center.
    Mult Scler; 2001 Feb 01; 7(1):33-41. PubMed ID: 11321192
    [Abstract] [Full Text] [Related]

  • 17. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
    Simpson D, Noble S, Perry C.
    CNS Drugs; 2002 Feb 01; 16(12):825-50. PubMed ID: 12421116
    [Abstract] [Full Text] [Related]

  • 18. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B.
    Rev Neurol (Paris); 2008 Nov 01; 164(11):917-26. PubMed ID: 18790510
    [Abstract] [Full Text] [Related]

  • 19. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM Study Investigators.
    N Engl J Med; 2012 Sep 20; 367(12):1087-97. PubMed ID: 22992072
    [Abstract] [Full Text] [Related]

  • 20. Neuropsychologic status in multiple sclerosis after treatment with glatiramer.
    Weinstein A, Schwid SR, Schiffer RB, McDermott MP, Giang DW, Goodman AD.
    Arch Neurol; 1999 Mar 20; 56(3):319-24. PubMed ID: 10190822
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.